These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 22142583

  • 1. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
    Ahmed FK, Clark BE, Burton DR, Pantophlet R.
    Vaccine; 2012 Jan 20; 30(5):922-30. PubMed ID: 22142583
    [Abstract] [Full Text] [Related]

  • 2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.
    J Virol; 2014 Dec 20; 88(24):14002-16. PubMed ID: 25253346
    [Abstract] [Full Text] [Related]

  • 3. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.
    Galkin A, Chen Y, Guenaga J, O'Dell S, Acevedo R, Steinhardt JJ, Wang Y, Wilson R, Chiang CI, Doria-Rose N, Grishaev AV, Mascola JR, Li Y.
    J Immunol; 2020 Mar 15; 204(6):1543-1561. PubMed ID: 32066595
    [Abstract] [Full Text] [Related]

  • 4. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R, Tuen M, Liu J, Nàdas A, Pan R, Kong X, Hioe CE.
    Vaccine; 2013 Nov 04; 31(46):5413-21. PubMed ID: 24051158
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparing antigenicity and immunogenicity of engineered gp120.
    Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR.
    J Virol; 2005 Oct 04; 79(19):12148-63. PubMed ID: 16160142
    [Abstract] [Full Text] [Related]

  • 7. An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.
    Yu HT, Tian D, Wang JY, Guo CX, Li Y, Wang X, Li D, Zhang FM, Zhuang M, Ling H.
    PLoS One; 2014 Oct 04; 9(12):e115047. PubMed ID: 25546013
    [Abstract] [Full Text] [Related]

  • 8. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, Beaumont D, Shen X, Yates NL, Pinter A, Tomaras GD, Ferrari G, Montefiori DC, Hu SL.
    J Virol; 2016 Oct 01; 90(19):8644-60. PubMed ID: 27440894
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines.
    Hioe CE, Kumar R, Upadhyay C, Jan M, Fox A, Itri V, Peachman KK, Rao M, Liu L, Lo NC, Tuen M, Jiang X, Kong XP, Zolla-Pazner S.
    Front Immunol; 2018 Oct 01; 9():2441. PubMed ID: 30416503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
    Shubin Z, Li W, Poonia B, Ferrari G, LaBranche C, Montefiori D, Zhu X, Pauza CD.
    Clin Vaccine Immunol; 2017 Jun 01; 24(6):. PubMed ID: 28404572
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
    Li Y, O'Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp CM, Louder MK, Longo NS, Poulsen C, Guenaga J, Chakrabarti BK, Doria-Rose N, Roederer M, Connors M, Mascola JR, Wyatt RT.
    J Virol; 2012 Oct 01; 86(20):11231-41. PubMed ID: 22875963
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
    Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR.
    J Virol; 2003 Jan 01; 77(1):642-58. PubMed ID: 12477867
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX, Cianciolo GJ, Staats HF, Scearce RM, Lapple DM, Stauffer SH, Thomasch JR, Pizzo SV, Montefiori DC, Hagen M, Eldridge J, Haynes BF.
    Vaccine; 2002 May 22; 20(17-18):2396-403. PubMed ID: 12009296
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.